Full Press Release Details
Phase 3 NORA data of ZEJULA (niraparib) demonstrate significant PFS benefit in Chinese women with platinum-sensitive recurrent ovarian cancer.
ZLAB
Phase 3 NORA data of ZEJULA (niraparib) demonstrate significant PFS benefit in Chinese women with platinum-sensitive recurrent ovarian cancer
Key Takeaway: Phase 3 NORA data of ZEJULA (niraparib) demonstrate significant PFS benefit in Chinese women with platinum-sensitive recurrent ovarian cancer